Prof. Dr. Stephan Weidinger
Anti-IL12/23(Prof. Dr. Stephan Weidinger)은 Atopic Dermatitis 표적 치료제로, Atopic Dermatitis; Psoriasis 영역에서 개발·상용화 중입니다. 작용기전: with high efficacy and safety profiles, sustained total skin clearance, and rapid onset of effect also to psoriasis patients who previously failed or experienced an inadequate resp. 전임상 단계입니다. ClinicalTrials.gov 기준 16건의 관련 임상이 등록되어 있습니다. 차별점: novel small molecules is needed to decrease complications and the need for hospitalization and surgery.
Atopic Dermatitis
Atopic Dermatitis; Psoriasis
Recruiting
humanized monoclonal anti-IL12/23 antibody with a good safety profile
novel small molecules is needed to decrease complications and the need for hospitalization and surgery
with high efficacy and safety profiles, sustained total skin clearance, and rapid onset of effect also to psoriasis patients who previously failed or experienced an inadequate response to anti-TNF-α or anti-IL12/2
immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life
biomarkers independently predicted survival
bypass graft [CABG])
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Prof. Dr. Stephan Weidinger
Anti-IL12/23(Prof. Dr. Stephan Weidinger)은 Atopic Dermatitis 표적 치료제로, Atopic Dermatitis; Psoriasis 영역에서 개발·상용화 중입니다. 작용기전: with high efficacy and safety profiles, sustained total skin clearance, and rapid onset of effect also to psoriasis patients who previously failed or experienced an inadequate resp. 전임상 단계입니다. ClinicalTrials.gov 기준 16건의 관련 임상이 등록되어 있습니다. 차별점: novel small molecules is needed to decrease complications and the need for hospitalization and surgery.
Atopic Dermatitis
Atopic Dermatitis; Psoriasis
Recruiting
humanized monoclonal anti-IL12/23 antibody with a good safety profile
novel small molecules is needed to decrease complications and the need for hospitalization and surgery
with high efficacy and safety profiles, sustained total skin clearance, and rapid onset of effect also to psoriasis patients who previously failed or experienced an inadequate response to anti-TNF-α or anti-IL12/2
immune-mediated disease with either skin or joints manifestations, or both, and it has a major impact on quality of life
biomarkers independently predicted survival
bypass graft [CABG])
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.